Oncology Central

2 weeks ago | oncology-central.com | Jade Parker

Objective responses observed with oral, investigational drug zoldonrasib for KRAS G12D-mutated NSCLC patients. Findings from a Phase I trial presented at the AACR Annual Meeting (25–30 April; Chicago, IL, USA) have highlighted encouraging efficacy reports of using zoldonrasib in NSCLC patients with KRAS G12D mutations.

2 weeks ago | oncology-central.com | Jade Parker

Read key news stories from the AACR 2025 Annual Meeting (25–30 April 2025, IL, USA), highlighting the latest advancements and discoveries in cancer research and treatment. AACR news headlinesIn an ongoing Phase I trial, a first-in-class off-the-shelf CAR NK cell therapy has achieved complete remission in patients with relapsed or refractory acute myeloid leukemia. “The deep and durable responses observed in patients for whom we have follow-up data are impressive.

2 months ago | oncology-central.com | Jade Parker

In this interview, Saiful Huq, PhD, FAAPM, FInstP (University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, PA, USA) discusses how the inadequate healthcare infrastructure and disparities in rural and urban areas lead to barriers to cancer care in South Asian Association for Regional Cooperation (SAARC) countries. Huq highlights the steps needed to overcome these barriers and how his latest research identifies evidence-based strategies to do so.

2 months ago | oncology-central.com | Jade Parker

A paste made from gallium-doped bioglass could have anticancer and bone regenerative properties. A collaboration between Aston University and The Royal Orthopaedic Hospital (both Birmingham, UK) to develop an injectable paste to treat bone cancer is set to take place thanks to a £110,000 grant from Orthopaedic Research UK (London) to the orthopedic hospital.

2 months ago | oncology-central.com | Jade Parker

The need to tackle the long-term effects of cancer and subsequent treatment is rapidly growing, particularly as survival rates of young cancer patients continue to rise. After endocrine health, . Oncofertility connects endocrine health and reproductive health, focusing on the unique challenges faced by cancer patients and survivors. As patients look forward to life after cancer, many face difficulties with fertility as a result of either their treatment or the disease itself.